NIAID’s ACTT-2: Hospitalized COVID-19 Patients Fare Better on Lilly’s Baricitinib & Remdesivir vs. Remdesivir Alone: Triggered FDA EUA in Nov. 2020

NIAID’s ACTT-2 Hospitalized COVID-19 Patients Fare Better on Lilly’s Baricitinib & Remdesivir vs. Remdesivir Alone Triggered FDA EUA in Nov. 2020

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), recently produced results from a clinical trial the research agency sponsored the ACTT-2 clinical trial formally titled, “A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults.” An adaptive randomized double-blind placebo-controlled trial evaluated the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. Involving about 100 trial site locations worldwide, the multicenter study compared different investigational therapeutic agents to the control arm. The study specifically investigated the combination of baricitinib and remdesivir as compared to remdesivir alone in 1,033 patients. The investigators found that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with COVID-19, especially among individuals receiving high-flow oxygen or noninvasive ventilation. Additionally, the combination of the two therapies involv...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee